Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.36 |
| ▸ | CDK1 | P06493 | 2/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20119874 | 1.00 | LMNA (0.43) | LMNAMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL15950870 | 0.81 | SMN1; SMN2 (0.39) | LMNAMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL15950871 | 0.80 | RPS6KB1 (0.39) | LMNAMEN1KMT2ASMN1; SMN2TP53 | |
| SCHEMBL14713436 | 0.79 | LMNA (0.64) | LMNASMN1; SMN2HSD17B10EGFRGALR3 | |
| SCHEMBL2623141 | 0.79 | LMNA (0.64) | LMNASMN1; SMN2HSD17B10EGFRGALR3 | |
| SCHEMBL5019518 | 0.79 | LMNA (0.64) | LMNASMN1; SMN2HSD17B10EGFRGALR3 | |
| SCHEMBL9801788 | 0.77 | SMN1; SMN2 (0.40) | LMNAMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL17009452 | 0.77 | KDM4E (0.39) | LMNAMEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL12186856 | 0.76 | LMNA (0.36) | LMNASMN1; SMN2HSD17B10 | |
| SCHEMBL15354439 | 0.76 | LMNA (0.36) | LMNASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953950-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | UNIV CALIFORNIA (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2020-09-10 | — | — | US | disclosed |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2018-03-15 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | MITOKININ, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2014124458-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072731-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | LMNA 188/4885MEN1 4250/4885KMT2A 3562/4885 |
| US-10723737-B2 | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | PINK1, CKMT1A; CKMT1B, NLN | LMNA 188/4885MEN1 4250/4885KMT2A 3562/4885 |
| US-20160108044-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | PINK1, CKMT1A; CKMT1B, NLN | LMNA 188/4885MEN1 4250/4885KMT2A 3562/4885 |
| US-20200283442-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND CARDIOMYOPATHY | SNCA, SMN1; SMN2, CLN6 | LMNA 77/4885MEN1 3137/4885KMT2A 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.